Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.60% | 19.06% | 20.36% | 36.79% | 58.38% |
| Gross Profit | -25.60% | -19.06% | -20.46% | -37.52% | -73.89% |
| SG&A Expenses | 48.05% | 49.72% | 55.05% | 45.62% | 41.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.48% | 25.44% | 27.52% | 38.73% | 54.47% |
| Operating Income | -30.48% | -25.44% | -27.61% | -39.31% | -65.75% |
| Income Before Tax | -30.51% | -22.90% | -22.21% | -28.74% | -45.85% |
| Income Tax Expenses | -1,300.34% | -142.40% | -145.50% | -121.20% | -347.46% |
| Earnings from Continuing Operations | -28.48% | -21.90% | -21.58% | -27.92% | -45.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.48% | -21.90% | -21.58% | -27.92% | -45.48% |
| EBIT | -30.48% | -25.44% | -27.61% | -39.31% | -65.75% |
| EBITDA | -31.46% | -26.06% | -26.79% | -38.33% | -65.08% |
| EPS Basic | -10.19% | -5.63% | -9.83% | -16.58% | -32.36% |
| Normalized Basic EPS | -9.77% | -3.35% | -7.73% | -16.81% | -39.23% |
| EPS Diluted | -10.19% | -5.63% | -9.83% | -16.58% | -32.36% |
| Normalized Diluted EPS | -9.77% | -3.35% | -7.73% | -16.81% | -39.23% |
| Average Basic Shares Outstanding | 16.45% | 15.16% | 10.86% | 10.43% | 11.31% |
| Average Diluted Shares Outstanding | 16.45% | 15.16% | 10.86% | 10.43% | 11.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |